David R. Scott
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David R. Scott has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- George Sachs
University of California at Los Angeles, and VA Greater Los Angeles Healthcare System
15 shared publications Elizabeth A. Marcus
Department of Pediatrics, David Geffen School of Medicine at UCLA and VA GLAHS, Los Angeles, CA, USA
13 shared publications- Elizabeth A. Marcus
Department of Pediatrics, DGSOM at UCLA, 10833 LeConte Ave., 12-383 MDCC, Los Angeles, CA 90095, USA
11 shared publications George Sachs
Department of Medicine, David Geffen School of Medicine at UCLA and VA GLAHS, Los Angeles, CA, USA
11 shared publicationsYi Wen
VA GLAHS, Los Angeles, CA, 90073, USA
9 shared publicationsJing Feng
Physiology, David Geffen School of Medicine at UCLA
6 shared publications
Latest Publications
- 25 April 2018
- Published by Wiley in Helicobacter
- Vol. 23 (3) , e12490
Acid‐regulated gene expression of Helicobacter pylori: Insight into acid protection and gastric colonization
Background: The pathogen Helicobacter pylori encounters many stressors as it transits to and infects the gastric epithelium. Gastric acidity is the predominate stressor encountered by the bacterium during initial infection and establishment of persistent infection. H. pylori initiates a rapid response to acid to maintain intracellular pH and proton motive force appropriate for a neutralophile. However, acid sensing by H. pylori may also serve as a transcriptional trigger to increase the levels of other pathogenic factors needed to subvert host defenses such as acid acclimation, antioxidants, flagellar synthesis and assembly, and CagA secretion.Materials and Methods: Helicobacter pylori were acid challenged at pH 3.0, 4.5, 6.0 vs nonacidic pH for 4 hours in the presence of urea, followed by RNA‐seq analysis and qPCR. Cytoplasmic pH was monitored under the same conditions.Results: About 250 genes were induced, and an equal number were repressed at acidic pHs. Genes encoding for antioxidant proteins, flagellar structural proteins, particularly class 2 genes, T4SS/Cag‐PAI, FoF1‐ATPase, and proteins involved in acid acclimation were highly expressed at acidic pH. Cytoplasmic pH decreased from 7.8 at pHout of 8.0 to 6.0 at pHout of 3.0.Conclusions: These results suggest that increasing extracellular or intracellular acidity or both are detected by the bacterium and serve as a signal to initiate increased production of protective and pathogenic factors needed to counter host defenses for persistent infection. These changes are dependent on degree of acidity and time of acid exposure, triggering a coordinated response to the environment required for colonization.
- 25 April 2018
- Published by Wiley in Helicobacter
- Vol. 23 (3) , e12490
Acid‐regulated gene expression of Helicobacter pylori: Insight into acid protection and gastric colonization
Background: The pathogen Helicobacter pylori encounters many stressors as it transits to and infects the gastric epithelium. Gastric acidity is the predominate stressor encountered by the bacterium during initial infection and establishment of persistent infection. H. pylori initiates a rapid response to acid to maintain intracellular pH and proton motive force appropriate for a neutralophile. However, acid sensing by H. pylori may also serve as a transcriptional trigger to increase the levels of other pathogenic factors needed to subvert host defenses such as acid acclimation, antioxidants, flagellar synthesis and assembly, and CagA secretion.Materials and Methods: Helicobacter pylori were acid challenged at pH 3.0, 4.5, 6.0 vs nonacidic pH for 4 hours in the presence of urea, followed by RNA‐seq analysis and qPCR. Cytoplasmic pH was monitored under the same conditions.Results: About 250 genes were induced, and an equal number were repressed at acidic pHs. Genes encoding for antioxidant proteins, flagellar structural proteins, particularly class 2 genes, T4SS/Cag‐PAI, FoF1‐ATPase, and proteins involved in acid acclimation were highly expressed at acidic pH. Cytoplasmic pH decreased from 7.8 at pHout of 8.0 to 6.0 at pHout of 3.0.Conclusions: These results suggest that increasing extracellular or intracellular acidity or both are detected by the bacterium and serve as a signal to initiate increased production of protective and pathogenic factors needed to counter host defenses for persistent infection. These changes are dependent on degree of acidity and time of acid exposure, triggering a coordinated response to the environment required for colonization.
- Open Access
- 19 July 2016
- Published by F1000 Research Ltd in F1000Research
- Vol. 5, 1747
The role of acid inhibition in Helicobacter pylori eradication
Infection of the stomach by the gastric pathogen Helicobacter pylori results in chronic active gastritis and leads to the development of gastric and duodenal ulcer disease and gastric adenocarcinoma. Eradication of H. pylori infection improves or resolves the associated pathology. Current treatments of H. pylori infection rely on acid suppression in combination with at least two antibiotics. The role of acid suppression in eradication therapy has been variously attributed to antibacterial activity of proton pump inhibitors directly or through inhibition of urease activity or increased stability and activity of antibiotics. Here we discuss the effect of acid suppression on enhanced replicative capacity of H. pylori to permit the bactericidal activity of growth-dependent antibiotics. The future of eradication therapy will rely on improvement of acid inhibition along with current antibiotics or the development of novel compounds targeting the organism’s ability to survive in acid.
- 19 July 2016
- Published by F1000 Research Ltd in F1000Research
- Vol. 5, 1747
Open AccessThe role of acid inhibition in Helicobacter pylori eradication
Infection of the stomach by the gastric pathogen Helicobacter pylori results in chronic active gastritis and leads to the development of gastric and duodenal ulcer disease and gastric adenocarcinoma. Eradication of H. pylori infection improves or resolves the associated pathology. Current treatments of H. pylori infection rely on acid suppression in combination with at least two antibiotics. The role of acid suppression in eradication therapy has been variously attributed to antibacterial activity of proton pump inhibitors directly or through inhibition of urease activity or increased stability and activity of antibiotics. Here we discuss the effect of acid suppression on enhanced replicative capacity of H. pylori to permit the bactericidal activity of growth-dependent antibiotics. The future of eradication therapy will rely on improvement of acid inhibition along with current antibiotics or the development of novel compounds targeting the organism’s ability to survive in acid.
- 13 May 2016
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 18 (7) , 1-9
Eradication of Helicobacter pylori Infection
Helicobacter pylori infects about 50 % of the world’s population, causing at a minimum chronic gastritis. A subset of infected patients will ultimately develop gastric or duodenal ulcer disease, gastric adenocarcinoma, or MALT (mucosa-associated lymphoid tissue) lymphoma. Eradication of H. pylori requires complex regimens that include acid suppression and multiple antibiotics. The efficacy of treatment using what were once considered standard regimens have declined in recent years, mainly due to widespread development of antibiotic resistance. Addition of bismuth to standard triple therapy regimens, use of alternate antibiotics, or development of alternative regimens using known therapies in novel combinations have improved treatment efficacy in specific populations, but overall success of eradication remains less than ideal. Novel regimens under investigation either in vivo or in vitro, involving increased acid suppression ideally with fewer antibiotics or development of non-antibiotic treatment targets, show promise for future therapy.
- 13 May 2016
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 18 (7) , 1-9
Eradication of Helicobacter pylori Infection
Helicobacter pylori infects about 50 % of the world’s population, causing at a minimum chronic gastritis. A subset of infected patients will ultimately develop gastric or duodenal ulcer disease, gastric adenocarcinoma, or MALT (mucosa-associated lymphoid tissue) lymphoma. Eradication of H. pylori requires complex regimens that include acid suppression and multiple antibiotics. The efficacy of treatment using what were once considered standard regimens have declined in recent years, mainly due to widespread development of antibiotic resistance. Addition of bismuth to standard triple therapy regimens, use of alternate antibiotics, or development of alternative regimens using known therapies in novel combinations have improved treatment efficacy in specific populations, but overall success of eradication remains less than ideal. Novel regimens under investigation either in vivo or in vitro, involving increased acid suppression ideally with fewer antibiotics or development of non-antibiotic treatment targets, show promise for future therapy.
- 13 April 2016
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (7) , 1783-1784
Vonoprazan: MarKed Competition for PPIs?
- 13 April 2016
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (7) , 1783-1784
Vonoprazan: MarKed Competition for PPIs?
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S36
146 Helicobacter pylori Infection Decreases Expression of the Na, K-ATPase in Gastric Epithelial Cells, Resulting in Acid-Induced Gastric Injury
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S36
146 Helicobacter pylori Infection Decreases Expression of the Na, K-ATPase in Gastric Epithelial Cells, Resulting in Acid-Induced Gastric Injury
- 4 January 2016
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 43 (3) , 443
Letter: vonoprazan, a long‐lasting acid suppressor of the gastric H+, K+‐ATPases with ‐ implications for renal H+, K+‐ATPases; authors' reply
- 4 January 2016
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 43 (3) , 443
Letter: vonoprazan, a long‐lasting acid suppressor of the gastric H+, K+‐ATPases with ‐ implications for renal H+, K+‐ATPases; authors' reply
- Open Access
- 30 September 2015
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 42 (11-12) , 1315-1326
The binding selectivity of vonoprazan (TAK‐438) to the gastric H+,K+‐ATPase
Summary: Background: The gastric H+,K+‐ATPase is the preferred target for acid suppression. Until recently, the only drugs that effectively inhibited this ATPase were the proton pump inhibitors (PPIs). PPIs are acid‐activated prodrugs that require acid protection. Once acid‐activated, PPIs bind to cysteines of the ATPase, resulting in covalent, long‐lasting inhibition. The short plasma half‐life of PPIs and continual de novo synthesis of the H+,K+‐ATPase result in difficulty controlling night‐time acid secretion. A new alternative to PPIs is the pyrrolo‐pyridine, vonoprazan (TAK‐438), a potassium‐competitive acid blocker (PCAB) that does not require acid protection. In contrast to other PCABs, vonoprazan has a long duration of action, resulting in 24‐h control of acid secretion, a high pKa of 9.37 and high affinity (Ki = 3.0 ηmol/L).Aim: To determine binding selectivity of vonoprazan for the gastric H+,K+‐ATPase and to explain its slow dissociation.Methods: Gastric gland and parietal cell binding of vonoprazan was determined radiometrically. Molecular modelling explained the slow dissociation of vonoprazan from the H+,K+‐ATPase.Results: Vonoprazan binds selectively to the parietal cell, independent of acid secretion. Vonoprazan binds in a luminal vestibule between the surfaces of membrane helices 4, 5 and 6. Exit of the drug to the lumen is hindered by asp137 and asn138 in the loop between TM1 and TM2, which presents an electrostatic barrier to movement of the sulfonyl group of vonoprazan. This may explain its slow dissociation from the H+,K+‐ATPase and long‐lasting inhibition.Conclusion: The binding model provides a template for design of novel potassium‐competitive acid blockers.
- 30 September 2015
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 42 (11-12) , 1315-1326
Open AccessThe binding selectivity of vonoprazan (TAK‐438) to the gastric H+,K+‐ATPase
Summary: Background: The gastric H+,K+‐ATPase is the preferred target for acid suppression. Until recently, the only drugs that effectively inhibited this ATPase were the proton pump inhibitors (PPIs). PPIs are acid‐activated prodrugs that require acid protection. Once acid‐activated, PPIs bind to cysteines of the ATPase, resulting in covalent, long‐lasting inhibition. The short plasma half‐life of PPIs and continual de novo synthesis of the H+,K+‐ATPase result in difficulty controlling night‐time acid secretion. A new alternative to PPIs is the pyrrolo‐pyridine, vonoprazan (TAK‐438), a potassium‐competitive acid blocker (PCAB) that does not require acid protection. In contrast to other PCABs, vonoprazan has a long duration of action, resulting in 24‐h control of acid secretion, a high pKa of 9.37 and high affinity (Ki = 3.0 ηmol/L).Aim: To determine binding selectivity of vonoprazan for the gastric H+,K+‐ATPase and to explain its slow dissociation.Methods: Gastric gland and parietal cell binding of vonoprazan was determined radiometrically. Molecular modelling explained the slow dissociation of vonoprazan from the H+,K+‐ATPase.Results: Vonoprazan binds selectively to the parietal cell, independent of acid secretion. Vonoprazan binds in a luminal vestibule between the surfaces of membrane helices 4, 5 and 6. Exit of the drug to the lumen is hindered by asp137 and asn138 in the loop between TM1 and TM2, which presents an electrostatic barrier to movement of the sulfonyl group of vonoprazan. This may explain its slow dissociation from the H+,K+‐ATPase and long‐lasting inhibition.Conclusion: The binding model provides a template for design of novel potassium‐competitive acid blockers.
- 4 August 2015
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 42 (7) , 922-933
Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth‐dependent antibiotics
Summary: Background: Successful eradication of Helicobacter pylori is becoming more difficult, mainly due to emerging antibiotic resistance. Treatment regimens containing bismuth have increased efficacy, but the mechanism is unknown. Helicobacter pylori is a neutralophile adapted to survive the acidic gastric environment via acid acclimation, but demonstrates more robust growth at neutral pH. Many antibiotics used to treat H. pylori rely on bacterial growth.Aim: To investigate the mechanism of increased efficacy of bismuth‐containing H. pylori treatment regimens.Methods: RNAseq and qPCR, urease activity in permeabilised and intact bacteria, internal pH and membrane potential were measured with and without colloidal bismuth subcitrate (CBS). Bacterial survival was assessed with CBS and/or ampicillin.Results: Genes involved with metabolism and growth were upregulated in the presence of CBS at acidic pH. Urease activity of permeabilised H. pylori at pH 7.4 and 4.5 decreased in the presence of CBS, but intact urease activity decreased only at acidic pH. The fall in cytoplasmic pH with external acidification was diminished by CBS. The increase in membrane potential in response to urea addition at acidic medium pH was unaffected by CBS. The impact of CBS and ampicillin on H. pylori survival was greater than either agent alone.Conclusions: Bismuth is not acting directly on urease or the urea channel. Colloidal bismuth subcitrate impedes proton entry into the bacteria, leading to a decrease in the expected fall in cytoplasmic pH. With cytoplasmic pH remaining within range for increased metabolic activity of a neutralophile, the efficacy of growth‐dependent antibiotics is augmented.
- 4 August 2015
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 42 (7) , 922-933
Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth‐dependent antibiotics
Summary: Background: Successful eradication of Helicobacter pylori is becoming more difficult, mainly due to emerging antibiotic resistance. Treatment regimens containing bismuth have increased efficacy, but the mechanism is unknown. Helicobacter pylori is a neutralophile adapted to survive the acidic gastric environment via acid acclimation, but demonstrates more robust growth at neutral pH. Many antibiotics used to treat H. pylori rely on bacterial growth.Aim: To investigate the mechanism of increased efficacy of bismuth‐containing H. pylori treatment regimens.Methods: RNAseq and qPCR, urease activity in permeabilised and intact bacteria, internal pH and membrane potential were measured with and without colloidal bismuth subcitrate (CBS). Bacterial survival was assessed with CBS and/or ampicillin.Results: Genes involved with metabolism and growth were upregulated in the presence of CBS at acidic pH. Urease activity of permeabilised H. pylori at pH 7.4 and 4.5 decreased in the presence of CBS, but intact urease activity decreased only at acidic pH. The fall in cytoplasmic pH with external acidification was diminished by CBS. The increase in membrane potential in response to urea addition at acidic medium pH was unaffected by CBS. The impact of CBS and ampicillin on H. pylori survival was greater than either agent alone.Conclusions: Bismuth is not acting directly on urease or the urea channel. Colloidal bismuth subcitrate impedes proton entry into the bacteria, leading to a decrease in the expected fall in cytoplasmic pH. With cytoplasmic pH remaining within range for increased metabolic activity of a neutralophile, the efficacy of growth‐dependent antibiotics is augmented.
- 22 May 2015
- Published by Wiley in Helicobacter
- Vol. 21 (1) , 69-81
Phosphorylation‐dependent and Phosphorylation‐independent Regulation of Helicobacter pylori Acid Acclimation by the ArsRS Two‐component System
Background: The pH‐sensitive Helicobacter pylori ArsRS two‐component system (TCS) aids survival of this neutralophile in the gastric environment by directly sensing and responding to environmental acidity. ArsS is required for acid‐induced trafficking of urease and its accessory proteins to the inner membrane, allowing rapid, urea‐dependent cytoplasmic and periplasmic buffering. Expression of ArsR, but not its phosphorylation, is essential for bacterial viability. The aim of this study was to characterize the roles of ArsS and ArsR in the response of H. pylori to acid.Materials and Methods: Wild‐type H. pylori and an arsR(D52N) phosphorylation‐deficient strain were incubated at acidic or neutral pH. Gene and protein expression, survival, membrane trafficking of urease proteins, urease activity, and internal pH were studied.Results: Phosphorylation of ArsR is not required for acid survival. ArsS‐driven trafficking of urease proteins to the membrane in acid, required for recovery of internal pH, is independent of ArsR phosphorylation. ArsR phosphorylation increases expression of the urease gene cluster, and the loss of negative feedback in a phosphorylation‐deficient mutant leads to an increase in total urease activity.Conclusions: ArsRS has a dual function in acid acclimation: regulation of urease trafficking to UreI at the cytoplasmic membrane, driven by ArsS, and regulation of urease gene cluster expression, driven by phosphorylation of ArsR. ArsS and ArsR work through phosphorylation‐dependent and phosphorylation‐independent regulatory mechanisms to impact acid acclimation and allow gastric colonization. Furthering understanding of the intricacies of acid acclimation will impact the future development of targeted, nonantibiotic treatment regimens.
- 22 May 2015
- Published by Wiley in Helicobacter
- Vol. 21 (1) , 69-81
Phosphorylation‐dependent and Phosphorylation‐independent Regulation of Helicobacter pylori Acid Acclimation by the ArsRS Two‐component System
Background: The pH‐sensitive Helicobacter pylori ArsRS two‐component system (TCS) aids survival of this neutralophile in the gastric environment by directly sensing and responding to environmental acidity. ArsS is required for acid‐induced trafficking of urease and its accessory proteins to the inner membrane, allowing rapid, urea‐dependent cytoplasmic and periplasmic buffering. Expression of ArsR, but not its phosphorylation, is essential for bacterial viability. The aim of this study was to characterize the roles of ArsS and ArsR in the response of H. pylori to acid.Materials and Methods: Wild‐type H. pylori and an arsR(D52N) phosphorylation‐deficient strain were incubated at acidic or neutral pH. Gene and protein expression, survival, membrane trafficking of urease proteins, urease activity, and internal pH were studied.Results: Phosphorylation of ArsR is not required for acid survival. ArsS‐driven trafficking of urease proteins to the membrane in acid, required for recovery of internal pH, is independent of ArsR phosphorylation. ArsR phosphorylation increases expression of the urease gene cluster, and the loss of negative feedback in a phosphorylation‐deficient mutant leads to an increase in total urease activity.Conclusions: ArsRS has a dual function in acid acclimation: regulation of urease trafficking to UreI at the cytoplasmic membrane, driven by ArsS, and regulation of urease gene cluster expression, driven by phosphorylation of ArsR. ArsS and ArsR work through phosphorylation‐dependent and phosphorylation‐independent regulatory mechanisms to impact acid acclimation and allow gastric colonization. Furthering understanding of the intricacies of acid acclimation will impact the future development of targeted, nonantibiotic treatment regimens.